Compare TROX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROX | CRVS |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2012 | 2016 |
| Metric | TROX | CRVS |
|---|---|---|
| Price | $5.04 | $14.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $6.36 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 2.6M | 718.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,898,000,000.00 | N/A |
| Revenue This Year | $6.94 | N/A |
| Revenue Next Year | $5.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.86 | $5.58 |
| 52 Week High | $10.59 | $26.95 |
| Indicator | TROX | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 32.27 | 48.10 |
| Support Level | $4.08 | $12.76 |
| Resistance Level | $5.25 | $16.66 |
| Average True Range (ATR) | 0.27 | 0.59 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 4.07 | 22.89 |
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.